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The historical paradigm of spontaneous bleeding tendency 
of cirrhosis as consequence of an intrinsic coagulopathy 
has faded in the last years (1). This theory has been 
first challenged by milestones studies of Tripodi et al. 
demonstrating normal thrombin generation by plasma 
from cirrhotic patients and, consequently, the need of more 
comprehensive coagulation tests to evaluate hemostatic 
changes in advanced chronic liver disease (2). This is 
coherent with the clinical observation of thrombotic 
events occurring among cirrhotic patients, despite altered 
prothrombin- and partial thromboplastin-time, which are 
inadequate to evaluate the profound changes in balance 
between pro- and anti-coagulant factors alongside the 
disruption of liver function (3,4). Moreover, plasma from 
patients with cirrhosis shows a pro-coagulant imbalance 
alongside disease severity, as expressed by the resistance 
to the action of thrombomodulin, a strong anti-coagulant 
factor (5). These pro-hemostatic properties are also 
associated with severe prognosis and probably concur in 
the worsening of liver function as consequence of liver 
microthrombosis and progressive parenchymal extinction 
(6,7). As a matter of fact, in a cardinal randomized 
controlled trial by Villa et al., the use of enoxaparin 
was associated with better survival and less events of 
decompensation, along with portal vein thrombosis (PVT) 
prevention (8). Thus, the impact of all these changes in 
hemostasis on the development of PVT has been of great 
interest in recent years with important clinical meanings, 
due to the high frequency of PVT in the natural history of 
cirrhosis and the potential pathogenic role of hemostasis as 
mediator of liver damage. Moreover, PVT per se may lead 
to several complications like development or worsening 
of ascites and variceal bleeding and may compromise 
the viability of liver transplantation (9). Besides heparin 
and vitamin-K antagonists and, possibly, new direct anti-
coagulants (10), little is known about other pharmacological 
strategies for prevention and treatment of PVT (9). 
Therefore, understanding the mechanisms of thrombus 
formation in chronic liver disease is crucial, due to the 
fragile hemostatic profile described in cirrhosis. 
We read with interest the recent paper by El-Makarem 
et al., which focuses on the potential contribution of 
inflammation in the pathophysiology of PVT (11). In this 
clinical study, authors analyzed several hemostatic parameters 
by comparing HCV-positive cirrhotic patients with PVT 
(n=30), cirrhotic patients without PVT (n=35), non-cirrhotic 
patients with PVT (n=15), and healthy controls (n=15). 
All patients with PVT were not on anticoagulation at time 
of inclusion. First, they confirmed the futility of standard 
coagulation tests to evaluate the hemostatic balance in 
cirrhosis, indeed no INR differences were detected between 
PVT and non-PVT group. Second, they found reduced 
levels of pro-coagulant factor VII in cirrhosis, as expected 
for the advanced liver disease (1), and, in both cirrhotic- 
and non-cirrhotic-PVT patients, found an increasing trend 
of FVII-AT complexes, which are considered markers of 
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endogenous activated coagulation (12). To evaluate the 
potential role of inflammatory stimuli in PVT development, 
they focused on microparticles analysis, particularly on 
monocytic tissue factor (TF). Microparticles are extracellular 
vesicles extensively studied in hemostasis due to the 
capability to carry on their surface pro-coagulant molecules, 
like TF or negatively charged phospholipids. Their 
secretion is the consequence of several inflammatory stimuli 
like endotoxemia or cancer-related inflammation (13). 
They have been investigated in different clinical contexts 
and, recently, in the development of neoplastic PVT (14). 
In their study, El-Makarem et al. found an increase of 
monocytic-TF in both PVT-groups, without differences 
between non-cirrhotic vs.cirrhotic-PVT. This suggests an 
influence of such pro-hemostatic particles despite of liver 
function decline. Interestingly, together with portal vein 
diameter, monocytic-TF was independently associated 
with PVT, confirming a strong association of immune-
inflammatory elements with thrombosis. Along with 
hemostatic parameters they found a reduction in HLA-
DR expression in PVT-groups and increased levels of 
monocyte co-stimulatory molecule CD46 independently 
by the presence of cirrhosis. These indexes of profound 
immunological disturbance (15,16) are coherent, although 
not specific, with the link between immune-system and 
hemostasis and warrant further investigations. The absence 
of differences between cirrhotic and non-cirrhotic PVT 
suggests the determinant role of immune system in the 
susceptibility to PVT whatever the degree of liver damage. 
Globally, the results of this study are in line with a 
recent pathophysiological theory, by Bernardi et al., which 
considers the chronic activation of inflammatory pathways, 
due to the progressive increase of bacterial translocation 
from the gut, the main culprit of the detrimental progression 
of cirrhosis toward an end-stage liver disease (17). 
The novelty of the paper lies on bridging inflammation 
and hemostasis through microparticles, extensively studied 
in hematology and oncology fields but only at dawn in 
hepatology. The study is also on the same track as other 
several basic-science studies, which have enlightened the 
potential of hemostasis as effector of the innate immune-
system and, in turn, thrombosis as an overexpression of a 
natural defense system. The term “immuno-thrombosis” 
synthetizes these theories (18). As El-Makarem underlines, 
TF-bearing microparticles may represent the link between 
immune activation and thrombus formation as they 
may origin from monocytes, neutrophils, endothelial 
cells, which have in common a potential activation by 
endotoxemia (19). Unfortunately, authors did not measure 
any bacterial by-product to correlate with microparticles, 
therefore the pathogenic scenario of endotoxemia as trigger 
of inflammation, although biologically plausible, remains 
undemonstrated by this experience. In addition, the design 
of the study allows only to reveal a simple association 
between TF-bearing microparticles and PVT. A proper 
cause-effect relation would have been better addressed by a 
cohort study considering different levels of microparticles as 
risk factors for PVT, possibly with a dose-effect relation, or 
by an intervention neutralizing TF-bearing microparticles 
with an effect on the risk of PVT. This notwithstanding, 
the pathogenic caveat may be overcome by other similar 
articles in the field. At today, we have learnt that the pro-
coagulant imbalance described in cirrhosis is sustained by 
high levels of factor VIII/protein C ratio and low levels of 
anticoagulants all correlating with the degree of plasma 
in vitro resistance to the action of thrombomodulin. These 
pro-hemostatic features are associated with worse prognosis, 
progression of the disease and translocation of bacterial 
products (7,20–22). A relevant weakness of the study by 
El-Makarem lies on the absence of measurement of these 
factors, as they are crucial players in the hemostatic balance, 
beside FVII (and FVII-AT complexes). Levels of FVII-
AT complexes alone do not fully evaluate the hemostatic 
balance and therefore, the predominance of the immune-
inflammatory component over the hypercoagulable state 
in the pathogenesis of PVT is an authors’ hypothesis 
which needs further explorations. Moreover, along with 
hemostasis, hemodynamic alterations of cirrhosis participate 
to the pathologic milieu prone to thrombus formation. 
Altered venous flow in portal system is a crucial element 
independently associated to PVT development (23). Thus, 
endothelial damage with the release of microparticles, 
von Willebrand factor (VWF) and TF, together with pro-
hemostatic proprieties of plasma and altered flow, all 
concur in the pathophysiology of cirrhosis and resemble the 
historical “Virchow’s triad”. This complex and intriguing 
interplay possibly clarifies the high prevalence of PVT in 
this population. These multiple interactions, ideally, offer 
many potential targets of therapy to prevent thrombus 
formation. In addition, recently, Tripodi et al. suggested 
that HCV-clearance could interfere with the pro-coagulant 
profile of plasma detected before antiviral treatment (24), 
but studies with larger cohorts are eagerly awaited to draw 
definitive conclusions on this topic. Notwithstanding, anti-
coagulation remains the cornerstone of PVT treatment, 
with beneficial risk-benefit ratio if the correct prophylaxis 
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of variceal bleeding is provided (25).
In conclusion, new theories recognize inflammation 
as a crucial factor in disease progression due to the 
influence on several pro-hemostatic triggers, like TF-
bearing microparticles, with thrombus formation and PVT 
development in cirrhosis. The understanding of these pro-
inflammatory, pro-hemostatic triggers may help to develop 
new diagnostic and therapeutic strategies to smother the 
pernicious impact of thrombosis on the natural history of 
cirrhosis.
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